Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ONO 1301

Drug Profile

ONO 1301

Alternative Names: AP-50002; ONO 1301 - slow-release; ONO-1301-MS; ONO-AP-500-02; SR-ONO

Latest Information Update: 28 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ono Pharmaceutical
  • Developer Ono Pharmaceutical; Osaka University
  • Class Acetic acids; Anti-inflammatories; Antiplatelets; Pyridines; Small molecules
  • Mechanism of Action Epoprostenol agonists; Prostaglandin agonists; Thromboxane synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Myocardial infarction; Myocardial ischaemia; Pulmonary fibrosis
  • Discontinued Thrombosis

Most Recent Events

  • 28 Dec 2022 No recent reports of development identified for preclinical development in Myocardial-ischaemia in Japan (Parenteral, Injection)
  • 26 Dec 2022 No development reported - Preclinical for Myocardial infarction in Japan (PO)
  • 13 Nov 2020 Preclinical development in Myocardial ischaemia is ongoing in Japan
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top